Xolair Allergic Asthma Population Should Not Be Restricted Except By Age
Executive Summary
Genentech/Novartis' Xolair allergic asthma patient population should not be restricted except by age, FDA's Pulmonary-Allergy Drugs Advisory Committee recommended May 15
You may also be interested in...
Xolair Push For Younger Patients Could Test Power Of Risk Management
FDA's Pulmonary-Allergy Drugs Advisory Committee will meet Nov. 18 to review the asthma drug to treat patients between six and 11 years of age.
Genentech Xolair Average Cost Is $10,000 A Year; Mid-July Launch Planned
Genentech/Novartis' allergic asthma treatment Xolair will cost about $10,000 a year for the average patient at mid-July launch
Genentech Xolair Average Cost Is $10,000 A Year; Mid-July Launch Planned
Genentech/Novartis' allergic asthma treatment Xolair will cost about $10,000 a year for the average patient at mid-July launch